ライフサイエンスコーパス: specific drug

1 atic fibroblast cells treated with an asthma-specific drug.

2 AT2 that can be utilized for making an ACAT2-specific drug.

3 eatment response in individual patients to a specific drug.

4 , and their relationship with endorsement of specific drugs.

5 ly been associated with adverse reactions to specific drugs.

6 unding is not associated with endorsement of specific drugs.

7 cells to open the prospect of developing IN-specific drugs.

8 effects produced by currently used anti-VEGF-specific drugs.

9 rds finding effective and safe kinetoplastid-specific drugs.

10 mising possibilities for the design of VEGFR-specific drugs.

11 uiescence and hence resistance to cell-cycle specific drugs.

12 heumatic syndromes have been associated with specific drugs.

13 e C-linker/CNBHD and may guide the design of specific drugs.

14 ding cleft residues influence recognition of specific drugs.

15 osis demonstrates the need for additional TB-specific drugs.

16 n cellular water permeability and screen AQP-specific drugs.

17 e structure-based methods to design receptor-specific drugs.

18 es the need for the development of norovirus-specific drugs.

19 ide synthesis, and to screen for eubacterial-specific drugs.

20 al PKC inhibitors but not by the classic PKC-specific drugs.

21 ause cancers acquire resistance to HER2/EGFR-specific drugs.

22 e regulatory mechanisms of the resistance to specific drugs.

23 onitor premanifest subjects and find patient-specific drugs.

24 ion pressures arising from population use of specific drugs.

25 altered in human HCC that may be targeted by specific drugs.

26 nt of carbohydrate based vaccines and target specific drugs.

27 nhibition of HSP90 function using the highly specific drugs 17-AAG, SNX-5422, or NVP-AUY922 reduced T

28 Part of the effort to develop hepatitis C-specific drugs a nd vaccines is the study of genetic var

29 tosoma japonicum The reason for this species-specific drug action has remained a mystery for decades.

30 Compartment-specific drug action was indeed observed.

31 sts, may hold potential for the treatment of specific drug addictions and psychiatric comorbidity.

32 ent information for the design of a safe and specific drug against T. brucei.

33 mately for structure-based design of subtype specific drugs against the nAChR associated diseases.

34 ctivation may aid in the development of more specific drugs against this target.

35 rived pK(a) values allows us to identify the specific drug amino groups whose protonation is linked t

36 Prevalence of specific drugs among decedents and proportion that had b

37 istration's approval of the first complement-specific drug, an antibody against complement component

38 Applications in the fields of sensors, site-specific drug and gene delivery or protein stabilization

39 timely predicting resistance of MTB given a specific drug and identifying resistance markers.

40 transporters, including the proximal tubule-specific drug and organic anion transporters (OATs) OAT1

41 ese data form the basis for rational, target-specific drug and vaccination therapies currently employ

42 nimum number of intravitreal injections of a specific drug and visual acuity interval.

43 ng GBO mutational profiles with responses to specific drugs and by modeling chimeric antigen receptor

44 ew targets for the development of alphavirus-specific drugs and directions for viral attenuation and

45 out improving medication use and withdrawing specific drugs and drug classes.

46 Early detection may enable development of specific drugs and early initiation of therapy, thereby

47 al setting for the development of metastasis-specific drugs and for patient stratification to optimiz

48 no clear associations have been made between specific drugs and HIV lipohypertrophy, stavudine and zi

49 ASM-specific drugs and multiple small interfering RNAs stron

50 ave been assigned through serotonin-receptor-specific drugs and mutants; however, because a constella

51 flush, combining hypothermia with mechanism-specific drugs and novel fluids; b) extension of suspend

52 ent effects in their responses to two A-site-specific drugs and on suppression nonsense codons.

53 Two non-specific drugs and one non-specific aptamer, tested as s

54 -1 drug resistance selection associated with specific drugs and regimens and the consequent activity

55 tensive published data sources and considers specific drugs and resistance mutations.

56 We calculated resistance scores for specific drugs and tallied major mutations to non-nucleo

57 ill allow the rational design of schistosome-specific drugs and vaccines.

58 yments (eg, speaking fees, meals) related to specific drugs, and $59 million for disease education.

59 No specific drugs are currently available against hepatitis

60 y against all four circulating serotypes nor specific drugs are currently available to treat this eme

61 ingestion and therapeutic effects of highly specific drugs are measurable on the basis of cell elect

62 responses of different cell-based assays to specific drugs are retained when three assays are co-pla

63 In this overview, we discuss specific drug-associated hemostatic complications, the a

64 achieved by modifying stem cells to release specific drugs at the site of transplantation.

65 onal adaptability of protein kinases towards specific drug binding.

66 ivity, thus a structural description of poly-specific drug-binding is important for the rational desi

67 also reveals a novel conformation for the K5-specific drug-binding loop 5, suggesting a possible role

68 es were moderate and generally similar among specific drugs, but larger among older antidepressants,

69 on of MCJ expression increases resistance to specific drugs by inducing expression of the ABCB1 drug

70 phase dynamics after exposure to the S phase specific drug, camptothecin.

71 ing, air pollution, infection, hormones, and specific drugs can contribute to this phenotype, other f

72 could be used for the development of enzyme-specific drug candidate compounds.

73 Finally, potential ancestry-specific and non-specific drug candidates were identified.

74 ts point to the necessity of developing site-specific drug carriers to improve the delivery of molecu

75 An AE-specific drug class effect is defined to exist when all

76 AE-specific drug class effects were also explored using ODA

77 nes and/or consensus documents on general or specific drug class-induced DHRs are available to suppor

78 Specific drug classes associated with otherwise unexplai

79 Increased cell viability and resistance to specific drug classes in the BM stroma-derived condition

80 used to determine the independent effects of specific drug classes on outcomes of interest.

81 The purported superiority of specific drug classes, notably angiotensin-converting en

82 When we examined more specific drug classes, results indicated that the ACE-I/

83 In recent years, more specific drugs, collectively known as biologics, have be

84 r hypothesis to efficiently generate disease-specific drug combinations in a vast chemical combinator

85 ivities may be therapeutically targeted with specific drug combinations.

86 a network principle-based reward for disease-specific drug combinations.

87 It has been possible to recommend specific drug concentration for betalactam antibiotics,

88 hip with a mixing network is used to achieve specific drug concentrations for drug titration experime

89 A total of 329 plasma- and 1,362 tissue-specific drug concentrations from 9 distinct lung lesion

90 The results demonstrate that the site-specific drug conjugation at the engineered Cys residue

91 h regard to therapeutic implications, NOTCH3-specific drugs could represent a valuable strategy to li

92 diverse human genetic backgrounds respond to specific drugs, creating the possibility of personalized

93 iased from fitting the structural content of specific drug databases to prediction models.

94 s for development of safer vesicles for site-specific drug delivery and controlled release at patholo

95 of nanoscale vehicles and entities for site-specific drug delivery and medical imaging after parente

96 might also be a promising platform for tumor-specific drug delivery and other Hsp70-based targeted th

97 g the biological barriers that hinder tissue-specific drug delivery and strategies to overcome them.

98 ey advances and emerging concepts for tissue-specific drug delivery approaches and their clinical tra

99 Externally controlled site specific drug delivery could potentially provide a means

100 veloping targeting strategies to enable site-specific drug delivery holds promise in reducing off-tar

101 nds that could serve as directive agents for specific drug delivery in hematologic malignancies.

102 However, effective ATII cell-specific drug delivery in vivo requires carriers of an a

103 (NPs) have also provided an opportunity for specific drug delivery into the tumor site.

104 Additionally, specific drug delivery issues, duration of therapy, init

105 o treat and when in their course of disease, specific drug delivery issues, duration of therapy, mana

106 e also discussed various techniques for site-specific drug delivery of anti-PAH therapeutics so as to

107 h a functionalized peptide that mediates the specific drug delivery opportunities with increased drug

108 of using these sequences to construct joint-specific drug delivery systems that may have considerabl

109 operties with applications ranging from site-specific drug delivery to anodes for lithium-ion batteri

110 s study demonstrates the feasibility of site-specific drug delivery to implanted magnetizable stents

111 Active targeting and specific drug delivery to parenchymal liver cells is a p

112 Efficient and specific drug delivery to the BM is an unmet need.

113 in provides an effective approach for tissue-specific drug delivery to the bone marrow.

114 rs for noninvasive, localized and temporally specific drug delivery to the rat brain.

115 and RAFT have significant potential for site-specific drug delivery to tissues with high levels of ox

116 vidual patient followed by optimized, target-specific drug delivery, may potentially improve efficacy

117 ide localization could be leveraged for site-specific drug delivery, while the decreased propensity o

118 yte that leads to a triggering mechanism for specific drug delivery.

119 nostructure carrying a high drug payload for specific drug delivery.

120 by the nanochain facilitates widespread site-specific drug delivery.

121 vestigated for multimodal imaging and target specific drug delivery.

122 l configurations of nanocarriers for disease-specific drug delivery.

123 ique for non-invasive gene therapy and organ-specific drug delivery.

124 here are limitations to their use for target specific drug delivery.

125 sh whether this approach can mediate cardiac-specific, drug-dependent excision between loxP sites in

126 ich could direct GlyR beta+/alpha- interface-specific drug design, but also provides a general method

127 ntial translational value in guiding disease-specific drug design.

128 of scleritis offers hope for future molecule-specific drug design.

129 lidate these residues as targets for species-specific drug design.

130 and can be an attractive target for pathway-specific drug design.

131 For specific drug development and to study distinct arrhythm

132 ue engineering, joint surgery, and cartilage-specific drug development.

133 PAK3 may thus represent such targets for p53-specific drug development.

134 the possibilities and challenges of pathway-specific drug development.

135 oach is an effective and robust tool for MCU-specific drug discovery and, more generally, for the ide

136 ide theoretical targets for tumor suppressor-specific drug discovery efforts.

137 sents a new class of PDE-based complexes for specific drug discovery targeting the cAMP signaling pat

138 channel gating and will facilitate organism-specific drug discovery.

139 ttern-learning approach to extract treatment-specific drug-disease pairs from 20 million biomedical a

140 rendered it sensitive to the otherwise mouse-specific drug DMXAA, a conclusion validated by binding s

141 notyping may be of value in planning patient-specific drug dosing.

142 alogues (octreotide) has replaced older less specific drugs (e.g. antihistamines) for the treatment o

143 ntitatively and simultaneously measure stage-specific drug effects on parasites at different developm

144 ls, yielding a restoration of ABCG2-mediated specific drug efflux activity.

145 ing clinical response to treatment with four specific drugs: etanercept, ustekinumab, adalimumab, and

146 quantify the signals of sex differences for specific drug-event combinations.

147 gest opportunities for the design of subtype-specific drugs exploiting cryptic pockets that open in c

148 Reward modulates the saliency of a specific drug exposure and is essential for the transiti

149 Together, the data suggest that specific drug-FABP complexes can interact with PPARalpha

150 cacies is critical in designing functionally specific drugs for GPCRs.

151 k in the skin could offer the development of specific drugs for novel treatment modalities.

152 ther excitable cells, there are virtually no specific drugs for this K+ channel.

153 ghts will facilitate the development of P2X7-specific drugs for treating human diseases.

154 The resulting specific drug formulation agents render insoluble drugs

155 for better understanding the release of this specific drug from vesicular phospholipid gel formulatio

156 tion of the Hsp90.PAR-1 complex by the Hsp90-specific drug geldanamycin attenuated thrombin-mediated

157 glycosylation has led to the development of specific drug glycoforms, for example, monoclonal antibo

158 also enhanced their sensitivity to the Ezh2-specific drug, GSK126 through increased growth inhibitio

159 No specific drug has been shown to prevent radiation-induce

160 Cell-based screening for novel tumor-specific drugs has been compromised by the lack of appro

161 Although several target-specific drugs have altered the paradigm of treatment fo

162 sistent with any serious lung disease, as no specific drugs have been approved as therapeutics.

163 Although VGSC beta subunit-specific drugs have not yet been developed, this protein

164 gs support the possible application of TORC2-specific drugs in cancer therapy.

165 se of manuscript writers, and endorsement of specific drugs in the abstract of the article.

166 The specific drug-induced electrolyte disorders discussed in

167 structural and functional bases of anti-VEGF-specific drug-induced side effects in relation to vascul

168 ouse and chemogenetic approach for cell-type-specific drug-inducible protein synthesis inhibition tha

169 We use cell-type-specific drug-inducible protein synthesis inhibition to

170 FVT sites received PDT according to specific drug infusion and laser light treatment paramet

171 um and Src family kinase dependent by use of specific drug inhibitors and dominant negative kinase tr

172 -HT1A/2A activation, either through receptor-specific drug intake, genetically predisposed irregular

173 e molecules in HNSCC and their inhibition by specific drug interaction; the relevance of these probes

174 r model can be a useful tool to study tissue-specific drug interactions and the effects of disease-re

175 ion to simplifying the simulation of variant specific drug interactions, the workflow enables large s

176 With the aid of specific drug intermediates and APIs, we chart the devel

177 Of specific drugs investigated, atazanavir, atazanavir/rito

178 ciated with autoimmune diseases, infections, specific drugs (levofloxacin, ustekinumab), and malignan

179 termine the permeability coefficient for the specific drug-lipid system.

180 studies have focused on interactions between specific drugs, little is known about the system propert

181 toid arthritis and developments of new, more specific drugs may be of particular benefit to patients

182 s obtained in a library screen, and to score specific drug-mediated disruption of protein-protein int

183 ect their blood levels, and the individual's specific drug-metabolizing enzyme profile may contribute

184 nal image analysis to quantify the uptake of specific drug molecules in skin without the need for lab

185 ovo design of telodendrimer nanocarriers for specific drug molecules, which is a promising approach t

186 fection in the presence of cocaine (Coc) and specific drugs namely i.e., tenofovir (Tef), rimcazole (

187 We therefore tested the effect of pathway-specific drugs on endurance capacities of mice in a trea

188 understanding of the mechanisms of action of specific drugs on the atrial substrate at different stag

189 ion, insights into the biological effects of specific drugs on transplanted cells are critical in ide

190 No approved specific drugs or vaccinations are available to treat th

191 onse to new infectious diseases for which no specific drugs or vaccines are available.

192 aths from 1999 to 2017, we show that the age-specific drug overdose mortality curve for each birth-ye

193 in PAH therapeutics with an emphasis on site-specific drug payload delivery.

194 We show that a CA-specific drug PF74 inhibits HIV-1 integration revealing

195 rk analysis, and ultimately predicts disease-specific drug polypharmacology through systems-based gen

196 Specific drug-protein interactions validate an allosteri

197 edback including alerts, reminders, and unit-specific drug rate limits.

198 rmine binding sites, bound conformations and specific drug-receptor interactions for several alloster

199 ationalize the mechanism of promiscuous, yet specific, drug recognition: (i) a four-ring motif presen

200 ervices, infant feeding recommendations, and specific drug regimens necessary to achieve this goal in

201 the first time, provides evidence of context-specific, drug-regulostat interactions in predetermining

202 The specific drug release can be achieved through a careful

203 or light have been developed to trigger site-specific drug release.

204 Cell cycle phase-specific drug resistance is an escape mechanism of melan

205 e household MDR strains were analyzed for 10 specific drug resistance-associated polymorphisms previo

206 ment of latent infection according to region-specific drug-resistance profiles could improve the effi

207 Region-specific drug-resistance profiles were derived from data

208 tinguish between generic stress response and specific drug response.

209 atrial and ventricular tissues with chamber-specific drug responses and gene expression.

210 Although patient-specific drug responses are common, for many patients, c

211 odel may prove useful for predicting patient-specific drug responses through in vitro patient-specifi

212 a provide evidence for CRC proteomic subtype-specific drug responses.

213 Treatment with various cytoskeleton-specific drugs revealed that the intact actomyosin motil

214 o two classes: (1) those that interfere with specific drug-ribosome interactions and (2) those that s

215 natomical categories of the drugs and to the specific drug routes of administration.

216 model of this type may allow insight into a specific drug's effects, which has potential to be usefu

217 llicit drug overdose deaths but obscures the specific drug(s) involved.

218 sed in vitro to predict and validate patient-specific drug safety and efficacy, potentially enabling

219 or resistant clones were detected with clone-specific drug screening.

220 or FCOIs are prevalent, and endorsement of a specific drug seems to be more common when authors have

221 We discover lineage-specific drug sensitivities based on subcategorization o

222 native tumours, useful for revealing patient-specific drug sensitivities.

223 domains were functional and exhibited family-specific drug sensitivity.

224 slation and hypersensitivity toward the eEF2-specific drug sordarin).

225 apable of predicting the immunity induced by specific drugs such as therapeutic vaccines and antibiot

226 er cells and targets for extremely lethal AT-specific drugs, such as bizelesin.

227 lementation requires evidence-based, context-specific drug-susceptibility testing (DST) strategies.

228 that accumulation of metabolites involved in specific drug target activity was linked to the buildup

229 er HTS of greater than 10(6) compounds for a specific drug target conclusively demonstrates a new app

230 es for the first time that TPP enables organ-specific drug target engagement and identification studi

231 data identify mutp53 as an actionable cancer-specific drug target.

232 n of its biosynthesis may provide a parasite-specific drug target.

233 , with a few exceptions, the disease lacks a specific drug target.

234 d thus may represent an example of a species-specific drug target.

235 pathology without prior identification of a specific drug target.

236 es, thereby offering a potential and species-specific drug target.

237 bacterial surface, which alter the nature of specific drug-target interactions.

238 ies, to a systematic construction of disease-specific drug-target networks.

239 Our approach can be used to make indication specific drug-target prediction by combining generic dru

240 Organ specific drug targeting was explored in mice as a possib

241 n of the peptides as vehicles for hepatocyte-specific drug targeting.

242 this interaction may lead to improved cancer-specific drug targeting.

243 rs and provide a template for designing more specific drugs targeting the folate receptor system.

244 y prove useful in identifying and validating specific drug targets and in deconvolving the effects of

245 the brain parenchyma, and the need for tumor-specific drug targets and pharmacologic agents to inhibi

246 trol APP expression and provide suitable and specific drug targets for AD.

247 cept in AF pathogenesis and may provide more specific drug targets for treating AF.

248 teractions between its driving mutations and specific drug targets.

249 egionally clustered samples are enriched for specific drug targets.

250 ation of tumor character and suggest subtype-specific drug targets.

251 eliciting better proxy for potential disease-specific drug targets.

252 ical roles of senescent cells and developing specific drug targets.

253 apped opportunities to discover new parasite-specific drug targets.

254 rs and present a unique platform for patient-specific drug testing.

255 effects but also correctly classify species-specific drug (Thalidomide) and false negative drug (D-p

256 g interactions, and developing efficient and specific drugs that alter ABC transporter function are h

257 and offers the prospect of designing pathway-specific drugs that avoid on-target side effects.

258 s makes the development of more potent, more specific drugs that behave like azacitidine imperative.

259 This work may lead to the design of specific drugs that can interrupt UL37 interactions with

260 RNA network, we focused on identification of specific drugs that can modulate miRNA expression and re

261 ed as an in vivo screening tool for genotype-specific drugs that enhance the effect of radiation ther

262 ble to build a safer generation of PPARgamma-specific drugs that evoke fewer side effects while prese

263 of the complex will facilitate the design of specific drugs that interfere with the S100A4-NMIIA inte

264 Thus, it may be possible to create myosin VI-specific drugs that rescue the function of deafness-caus

265 omeostasis and will allow the development of specific drugs that stimulate or inhibit these pathways.

266 The development of specific drugs that target one or more of these PLA2 enz

267 es are important for developing functionally specific drugs that will stabilize a particular receptor

268 associations observed are due to the use of specific drugs, the use of specific procedures, or the u

269 Frequently cited reasons for this absence of specific drug therapies include the heterogeneity of pat

270 echanisms, and potentially to tailor patient-specific drug therapy.

271 trategy to safely induce drug tolerance to a specific drug to limit the possibility of a type I react

272 The lack of vaccines or specific drugs to prevent or treat HFRS and HCPS and the

273 There are no vaccines or specific drugs to prevent or treat HPS, and the pathogen

274 This information may help in the design of specific drugs to prevent this condition.

275 , in combination therapies with other cancer-specific drugs, to maximize tumor cell killing while pro

276 e confirmed by analyzing isolated samples of specific drug-to-antibody ratio species.

277 e is truly localised in the context of organ-specific drug toxicity.

278 No specific drug treatment exists for MERS and infection pr

279 acute pancreatitis (AP), a condition without specific drug treatment.

280 evelopmental condition that currently has no specific drug treatment.

281 to predict the response of tumor cells to a specific drug treatment.

282 t data on protease mutations associated with specific drug treatments and mutations with positive rep

283 The role of specific drug treatments in the etiology of solid cancer

284 ls was determined by assaying the effects of specific drug treatments on the level of virus entry as

285 ific drug responses through in vitro patient-specific drug trials.

286 nd the absence of peripheral T-cell lymphoma-specific drugs, until recently at least, have limited th

287 Quantifying lesion-specific drug uptake and pharmacokinetics (PKs) in TB pa

288 lution likely has been influenced by country-specific drug use regimens.

289 t, but that the effects are dependent on the specific drugs used during pregnancy.

290 ticipants did not express concerns about the specific drugs used for IPTc or about providing tablets

291 cohorts may be more successful than mediator-specific drugs used indiscriminately.

292 ansplant short-term results, and the lack of specific "drugs" used for this disease.

293 The absence of approved parasite-specific drugs, vaccines, and immunotherapies for crypto

294 Kinase activity inhibition using a specific drug validated a role for Taok2 in favoring Lm

295 disease pathogenesis, and performing patient-specific drug validation.

296 used a simple binary contrast (exposure to a specific drug vs no exposure), which has potentially ser

297 No specific drug was significantly associated with remissio

298 Endorsement of specific drugs was significantly associated with author

299 RT inhibitors (NNRTIs) are a class of highly specific drugs which bind to a pocket approximately 10 A

300 tural similarity to the topoisomerase IIbeta-specific drug XK469, CQS was tested and found to be both